Biosenz B.V. – A Lavoisier Company - Zernikepark 16 9747AN Groningen – 050 8508960- info@biosenz.nl - www.biosenz.nl

ViriChip™ System:

A platform technology for virus

detection and identification

Johan Oosterheert, Managing directorSeptember 24, 2015

9/28/2015 Strictly confidential

New 'Sars-like' coronavirus identified by UK officialsBy Michelle Roberts Health editor, BBC News online, September 2012

A new respiratory illness similar to the Sars virus that spread globally in 2003 and killed hundreds

of people has been identified in a man who is being treated in Britain. The 49-year-old man, who

was transferred to a London hospital by air ambulance from Qatar, is the second person confirmed

with the corona virus. The first case was a patient in Saudi Arabia who has since died. Officials are

still determining what threat the new virus may pose.

Infectious viruses pose a serious threat

to public health

• Current diagnostic systems for viruses use central labs• Identification may take several days

ViriChip™ shortens response time

dramatically

9/28/2015 Strictly confidential

The ViriChip™ System brings the Lab to the field!

The ViriChip™ System:

• Size of a shoe box

• On-the-spot detection and identification

• 30 minutes response time

ViriChip™ is a unique, patented

lab-on-a chip technology

9/28/2015 Strictly confidential

Nano - and Biotechnology Atomic Force Microscopy

Ligand capture

Biosenz holds exclusive world-wide license on several patents

Biosenz has validated the technology

9/28/2015 Strictly confidential

Silicon chip including antibodies with Coxsackie B3 virus attached

Biosenz has validated 15 different viruses

ViriChip offers sensitivity, specificity,

ease of use and speed

9/28/2015 Strictly confidential

ViriChip PCR Immunoassays

Immunoelectron

Microscopy

Cell culture RAMP

Responsetime

Integral cost/test

Sensitivity

Specificity

Portability

Ease of use

Bulk processing

Biosenz intends to sell Virichip in

multiple markets

9/28/2015 Strictly confidential

1 2 3 4 5 6 7 8

Veterinary

Food

Clinical Markets

CDC, Homeland Security,Defense

Research Institutes

US Bio-defense busget $ 6.4 Bln. In

2012

World In-vitro diagnostic market $ 40 Bln. (2010)

POCT for infectious diseases $ 843 M (2011); 14% CAGR

Biosenz operates as a network organization

9/28/2015 Strictly confidential

ViriChip presents a unique opportunity

• Current diagnostic methods used to identify viruses use central labs and take days

• ViriChip technology brings the lab to the field, reducing response time to ~30 minutes

• Significant market potential

• Limited risk through business model and team

9/28/2015 Strictly confidential

Thank you for your attention.

9/28/2015 Strictly confidential